Environmentally benign, one-pot synthesis of pyrans by domino Knoevenagel/6π-electrocyclization in water and application to natural products
作者:Ene Jin Jung、Byung Ho Park、Yong Rok Lee
DOI:10.1039/c0gc00265h
日期:——
In water medium, environmentally benign, facile, and efficient synthesis of pyrans was achieved in good yields by the reactions of a variety of cyclic 1,3-dicarbonyls with several α,β-unsaturated aldehydes. The key strategy was a formal [3+3] cycloaddition by domino Knoevenagel/6Ï- electrocyclization. This methodology was applied to the synthesis of biologically interesting pyranocoumarin, pyranoquinolinone, and pyranonaphthoquinone derivatives along with selected natural and non-natural products.
Microwave-Assisted Solvent and Catalyst Free Synthesis of 2H-Pyrans
作者:Naushad Edayadulla、Yong Rok Lee
DOI:10.5012/bkcs.2013.34.10.2963
日期:2013.10.20
This paper describes a simple and efficient method involving domino Knovenegal/$6\pi}$ electrocyclization for the preparation of a variety of 2H-pyrans using microwave irradiation under solvent- and catalyst-free conditions. This method offers the advantages of a green approach, high yields, and short reaction times. Sixteen compounds (9a-p) were obtained in good to excellent yields using the procedure.
The invention discloses compounds of Formula (I)
wherein R
1
, R
2
, R
2A
, R
3
, R
3A
, R
4
, and R
5
are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.
Kraus, George A.; Wan, Zhiwen, Synlett, 2000, # 3, p. 363 - 364
作者:Kraus, George A.、Wan, Zhiwen
DOI:——
日期:——
TERTIARY AMIDES AND METHOD OF USE
申请人:AbbVie Inc.
公开号:US20190119200A1
公开(公告)日:2019-04-25
Compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein G
1
, G
2
, G
3
, L
1
, L
2
, and L
3
are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by the modulation of lysophosphatidic acid receptor 1. Methods for making the compounds are described. Also described are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.